Daicel Corp. (TYO:4202) is making preparations to launch a medical business for 2024. On top of bringing together the handling of drug administration and other such medical devices – along with peripheral materials – from under the control of its various businesses to form a single organization, Daicel plans to bring in pharmacokinetic evaluation technology from outside to add to this new core. Aims are to pursue M&A and collaborations with the likes of evaluation reagent and equipment manufacturers as the company looks to develop this into an overseas-centered business entity.
展开▼
